Skip to main content

Table 3 Risk of long-term adverse outcomes based on CIDs in the first 12 months of the ECLIPSE study

From: Long-term outcomes following first short-term clinically important deterioration in COPD

Outcome within 130 weeks of follow-up

CID+ population (N = 1442)

CID- population (N = 531)

CID+ vs CID-, HR (95% CI)

Moderate/severe COPD exacerbation, n (%)

1082 (75)

232 (44)

2.54 (2.20, 2.93)*

Hospitalization events, n (%)

454 (31)

66 (12)

2.81 (2.17, 3.63)*

Risk (HR) of all-cause mortality, n (%)

121 (8)

27 (5)

1.59 (1.04, 2.41)†

  1. *P < 0.001; P = 0.031
  2. CID clinically important deterioration, CID+ presence of a CID within 6 months of enrollment into the study, CID- absence of a CID within 6 months of enrollment into the study, ECLIPSE Evaluation of COPD Longitudinally to Identify Predictive Surrogate End-points, FEV1 forced expiratory volume in 1 s, HR hazard ratio, ITT intent-to-treat, SGRQ St George’s Respiratory Questionnaire